Colorectal (Colon) Cancer Clinical Trials: Stage, Biomarkers, and Treatment History

Colon cancer is often treated with surgery first when the disease is limited to the bowel and nearby lymph nodes. After surgery, some people are offered chemotherapy to lower the chance that the cancer returns. Trials in this setting are called adjuvant trials, and they may look at which treatment to give or who needs it.

Rectal cancer sits in a tight space in the pelvis, and the plan often starts before surgery, with chemotherapy, radiation, or both. Some approaches give all of the chemotherapy and radiation first (sometimes called total neoadjuvant therapy), and some people may be offered a way to avoid surgery if the tumor responds fully. Rectal studies often have their own protocol and eligibility rules, so a study listed for colon cancer should not be assumed to accept rectal cancer, and the other way around.

When the cancer has spread, most trials are built around metastatic disease. They may ask whether the cancer can be removed or treated locally, which drug combination to use first, or what to try after earlier treatments stop working. A first-line study (for people who have not yet had treatment for metastatic disease) is not the same as a study after one or more earlier lines of treatment.

Previous surgery, chemotherapy, targeted drugs, and immunotherapy can each be required in one study and excluded in another. Discuss the timing of any trial search with the oncologist rather than delaying recommended care while looking.

The plain-language clinical trial glossary can help with terms such as adjuvant, first-line, and standard of care.

Tumor test results that separate one trial from another

The pathology and molecular reports are the starting point. They describe the tumor tissue and, when ordered, the gene changes and proteins in it. Ask for copies, because many trials ask for the actual results.

MSI-high or dMMR (mismatch repair deficient) describes a tumor that cannot repair certain DNA copying errors. It is tested in colorectal cancer because it can point to immunotherapy, and because it can be linked to an inherited condition such as Lynch syndrome. A tumor that is MSS or pMMR (mismatch repair proficient) is a different group, and studies often enroll one group or the other.

KRAS and NRAS (together called RAS) are genes that can carry changes that matter for treatments aimed at the EGFR protein, such as cetuximab and panitumumab. Those drugs are generally not used when a RAS change is present, so a study may require "RAS wild type" or a specific variant. Some KRAS changes, such as KRAS G12C, are the target of newer drugs in their own right, and trials may be built around them.

BRAF V600E is a specific change in the BRAF gene. It is a distinct subgroup with its own treatment studies, and some trials require it while others exclude it.

HER2 is a protein or gene copy-number result that is checked in some metastatic cases. When it is present, certain targeted combinations may be an option, and some studies require it.

Other items on the report can matter too: where the tumor started in the colon, blood tests such as CEA, scan results, and tests after surgery that look for leftover tumor DNA in the blood, which some adjuvant studies use. These are not all biomarkers, but they can affect eligibility. There is no single panel that makes someone eligible for every colorectal cancer trial.

Some treatments mentioned here are already approved in defined settings. Availability depends on the test results, previous treatment, and the country where care is given.

Recruiting colorectal cancer trials

Start with the exact location (colon or rectum), the stage, and the test results, then check the study's criteria for previous treatment. A listing that includes "colorectal cancer" may still accept only one stage, one biomarker group, or people at one point in treatment. Confirm eligibility and local recruitment with the study team.

Open the full TrialFinder search for colorectal cancer.

Questions to ask an oncologist

A short list is usually enough:

• Is the cancer in the colon or the rectum, and what is the stage? Is the goal of treatment to remove the cancer, lower the chance it returns, or control it long term?
• Which tumor tests were done: MSI/dMMR, KRAS and NRAS, BRAF, HER2? Can I get a copy of the results? Are any tests still missing?
• Which treatments have I already had, and how did the cancer respond? Does earlier surgery, chemotherapy, or immunotherapy affect what is open to me?
• For this stage and these results, what is approved or considered standard where I live? Would looking for a trial delay treatment that should start now?
• Are there recruiting trials that match this exact profile, and how do their treatment, risks, and visit schedule differ from standard care?

Want to prepare for the appointment? The guide How to Talk to Your Doctor About Clinical Trials explains how to raise the topic and what to bring with you.

Sources

• NCI: Colorectal cancer
• NCI PDQ: Colon cancer treatment (patient)
• NCI PDQ: Rectal cancer treatment (patient)
• NCI PDQ: Colon cancer treatment (health professional)
• NCI PDQ: Rectal cancer treatment (health professional)
• NCI: Cancer staging
• NCI: Immunotherapy to treat cancer
• Study eligibility and recruitment information should be checked against the individual record on ClinicalTrials.gov and confirmed with the study team.

This article was written by a patient advocate based on personal experience, not by a medical professional. It is not medical advice. Consult your doctor before making any medical decisions.